A multicenter phase II study of low-dose erlotinib in frail patients with EGFR mutation-positive, non-small cell lung cancer: Thoracic oncology research group (TORG) trial 1425.

被引：2

作者：

Yamada, Kazuhiko

Miyamoto, Shingo

Azuma, Koichi

Ishii, Hidenobu

Bessho, Akihiro

Fukamatsu, Nobuaki

Kunitoh, Hideo

Ishii, Mari

Tanaka, Hiroshi

Aono, Hiromi

Nakahara, Yoshiro

Kusaka, Kei

Hosomi, Yukio

Kikuchi, Norihiro

Mori, Yoshiaki

Itani, Hidetoshi

Kasai, Takashi

Ichiki, Masao

Seki, Nobuhiko

Okamoto, Hiroaki

机构：

[1] Kurume Univ, Sch Med, Div Respirol Neurol & Rheumatol, Dept Internal Med, Kurume, Fukuoka, Japan

[2] Japanese Red Cross Med Ctr, Tokyo, Japan

[3] Japanese Red Cross Okayama Hosp, Okayama, Japan

[4] Yokohama Municipal Citizens Hosp, Yokohama, Kanagawa, Japan

[5] Niigata Canc Ctr Hosp, Dept Resp Med, Niigata, Japan

[6] Mitsui Mem Hosp, Tokyo, Japan

[7] Kitasato Univ, Sch Med, Sagamihara, Kanagawa, Japan

[8] Tokyo Natl Hosp, Natl Hosp Org, Tokyo, Japan

[9] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, Tokyo, Japan

[10] Kasumigaura Med Ctr, Tsuchiura, Ibaraki, Japan

[11] Iwate Cent Prefectural Hosp, Morioka, Iwate, Japan

[12] Japanese Red Cross Ise Hosp, Ise, Japan

[13] Tochigi Canc Ctr, Dept Resp Med, Utsunomiya, Tochigi, Japan

[14] Kyushu Med Ctr, Fukuoka, Fukuoka, Japan

[15] Teikyo Univ, Sch Med, Tokyo, Japan

[16] Yokohama Municipal Citizens Hosp, Dept Resp Med & Med Oncol, Yokohama, Kanagawa, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.9063

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9063

引用

页数：1

共 50 条

[41] A study of high dose furmonertinib in EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancer
Hu, Song
Ming, Hao
He, Qian
Ding, Ming
Ding, Hao
Li, Chong
FRONTIERS IN ONCOLOGY, 2024, 14
[42] Phase II trial of daily low-dose carboplatin and thoracic radiotherapy in elderly patients with locally advanced non-small cell lung cancer
Atagi, S
Kawahara, M
Ogawara, M
Matsui, K
Masuda, N
Kudoh, S
Negoro, S
Furuse, K
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2000, 30 (02) : 59 - 64
[43] Multicenter study of zoledronic acid administration in non-small-cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017
Nakahara, Yoshiro
Hosomi, Yukio
Shibuya, Masahiko
Mitsufuji, Hisashi
Katagiri, Masato
Naoki, Katsuhiko
Soejima, Kenzo
Nogami, Naoyuki
Nagase, Seisuke
Nishikawa, Masanori
Minato, Koichi
Takiguchi, Yuichi
Seki, Nobuhiko
Yamada, Kouzo
Seto, Takashi
Okamoto, Hiroaki
MOLECULAR AND CLINICAL ONCOLOGY, 2019, 11 (04) : 349 - 353
[44] EGFR mutation-based phase II multicenter trial of gefitinib in advanced non-small cell lung cancer (NSCLC) patients (pts): Results of West Japan Thoracic Oncology Group trial (WJTOG0403).
Okamoto, I.
Kashii, T.
Urata, Y.
Hirashima, T.
Kudoh, S.
Ichinose, Y.
Ebi, N.
Satoh, T.
Tamura, K.
Fukuoka, M.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 382S - 382S
[45] EGFR mutation-based phase II multicenter trial of gefitinib in advanced non-small cell lung cancer (NSCLC) patients (PTS): Results of West Japan Thoracic Oncology Group Trial (WJTOG0403)
Kashii, Tatsuhiko
Okamoto, Isamu
Urata, Yoshiko
Hirashima, Tomonori
Kudoh, Shinzo
Ichinose, Yukito
Ebi, Noriyuki
Satoh, Taroh
Tamura, Kenji
Fukuoka, Masahiro
ANNALS OF ONCOLOGY, 2006, 17 : 215 - 215
[46] Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study
Xiong, Liwen
Li, Rong
Sun, Jiayuan
Lou, Yuqing
Zhang, Weiyan
Bai, Hao
Wang, Huiming
Shen, Jie
Jing, Bo
Shi, Chunlei
Zhong, Hua
Gu, Aiqin
Jiang, Liyan
Shi, Jianxing
Fang, Wentao
Zhao, Heng
Zhang, Jie
Wang, Junyuan
Ye, Junyi
Han, Baohui
ONCOLOGIST, 2019, 24 (02): : 157 - +
[47] ASPIRATION: Phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
Park, Keunchil
Tsai, Chun-Ming
Ahn, Myung-ju
Yu, Chong-Jen
Kim, Sang-We
Sriuranpong, Virote
Kuo, Han Pin
Lee, Jong-Seok
Kang, Jin Hyoung
Lin, Meng-Chih
Geater, Sarayut Lucien
Chang, Gee-Chen
Seetalarom, Kasan
So, Ping Fai Peter
Lai, Ruay-Sheng
Cheng, Ashley Chi Kin
Cho, Eun Kyung
Chen, Shang-Hung
Hsia, Te-Chun
Mok, Tony
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[48] Cardiac Safety Assessment of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer
Haddish-Berhane, N.
Cho, B. C.
Ahn, M.
Han, J.
Kim, S.
Lee, K. H.
Cho, E. K.
Mehta, J.
Xie, J.
Shreeve, S. M.
Knoblauch, R. E.
Freeman, J.
Roshak, A.
Jang, S. B.
Lee, H.
Kang, S.
Kim, K. B.
Oh, S.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S677 - S678
[49] Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer?
Watanabe, Satomi
Hayashi, Hidetoshi
Nakagawa, Kazuhiko
ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (11)
[50] FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer
Kazandjian, Dickran
Blumenthal, Gideon M.
Yuan, Weishi
He, Kun
Keegan, Patricia
Pazdur, Richard
CLINICAL CANCER RESEARCH, 2016, 22 (06) : 1307 - 1312

← 1 2 3 4 5 →